Clinical Trial Update: A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia [Phase 3]

View source ↗

Summary

A Phase 3 trial is evaluating the safety and efficacy of subcutaneous Efgartigimod in adults with primary immune thrombocytopenia. The study is currently active…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Efgartigimod (efgartigimod)

Snippet

Sponsor: argenx | Conditions: Primary Immune Thrombocytopenia | Phase 3 | Status: ACTIVE_NOT_RECRUITING